Review section
Hepatic peroxisome proliferation in rodents and its significance for humans

https://doi.org/10.1016/0278-6915(93)90225-NGet rights and content

Abstract

Peroxisomes are subcellular organelles found in all eukaryotic cells. In the liver they are usually round and measure about 0.5–1.0 μm; in rodents they contain a prominent crystalloid core, but this may be absent in newly formed rodent peroxisomes as well as in human peroxisomes. A major role of the peroxisomes is the breakdown of long-chain fatty acids, thereby complementing mitochondrial fatty-acid metabolism. Many chemicals are known to increase the number of peroxisomes in rat and mouse hepatocytes. This peroxisome proliferation is accompanied by replicative DNA synthesis and liver growth. No clear structure-activity relationships are apparent. Many of these peroxisome proliferators contain acid functions that can modulate fatty acid metabolism. Two mechanisms have been proposed for the induction of peroxisome proliferation. One is based on the existence of one or several specific cytosolic receptors that bind the peroxisome proliferator, facilitating its translocation to the cell nucleus and the activation of the expression of specific genes. The second, perhaps more general, hypothesis involves chemically mediated perturbation of lipid metabolism. These two hypotheses are not mutually exclusive. Many peroxisome proliferators have been shown to induce hepatocellular tumours, despite being uniformly non-genotoxic, when administered at high dose levels to rats and mice for long periods. Three mechanisms have been proposed to explain the induction of tumours. One is based on increased production of active oxygen species due to imbalanced production of peroxisomal enzymes; it has been proposed that these reactive oxygen species cause indirect DNA damage with subsequent tumour formation. In rodents, an alternative mechanism is the promotion of endogenous lesions by sustained DNA synthesis and hyperplasia. Thirdly, it is conceivable that sustained growth stimulation may be sufficient for tumour formation. Marked species differences are apparent in response to peroxisome proliferations. Rats and mice are extremely sensitive, and hamsters show an intermediate response while guinea pigs, monkeys and humans appear to be relatively insensitive or non-responsive at dose levels that produce a marked response in rodents. These species differences may be reproduced in vitro using primary culture hepatocytes isolated from a variety of species including humans. The available experimental evidence suggests a strong association and a probable casual link between peroxisome-proliferator-elicited liver growth and the subsequent development of liver tumours in rats and mice. Since humans are insensitive or unresponsive, at therapeutic dose levels, to peroxisome-proliferator-induced hepatic effects, it is reasonable to conclude that the encountered levels of exposure to these non-genotoxic agents do not present a hepatocarcinogenic hazard to humans. This conclusion is supported by the available, albeit limited, epidemiological data.

References (275)

  • F. Bieri et al.

    Studies on the mechanism of induction of microsomal cytochrome P450 and peroxisomal bifunctional enzyme mRNAs by nafenopin in primary cultures of adult rat hepatocytes

    Biochemical Pharmacology

    (1991)
  • F. Bieri et al.

    The significance of in vitro studies on peroxisomal proliferation

    Toxicology in Vitro

    (1990)
  • B.J. Blaauboer et al.

    The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes

    Biochemical Pharmacology

    (1990)
  • S. Blumcke et al.

    Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients

    Atherosclerosis

    (1983)
  • A.J. Bone et al.

    Increased activity of peroxisomal β-oxidation in rat liver caused by ethyl 2[5(4-chlorophenyl)pentyl]-oxirane-2-carboxylate; an inhibitor of mitochondrial β-oxidation

    Biochemical and Biophysical Research Communications

    (1982)
  • J. Bremer et al.

    Metabolism of very long chain monounsaturated fatty acids (22:1) and the adaptation to their presence in the diet

    Journal of Lipid Research

    (1982)
  • E.G. Butler et al.

    Toxicological studies on a benzofurane derivative

  • D.M. Capuzzi et al.

    Stimulation of fatty acid utilisation by sodium clofibrate in rat and monkey hepatocytes

    Biochemical Pharmacology

    (1983)
  • R.C. Cattley et al.

    Association of persistent peroxisome proliferation and oxidative injury with hepatococarcinogenicity in female F-344 rats fed di(2-ethylhexyl)phthalate for 2 years

    Cancer Letters

    (1987)
  • R.C. Cattley et al.

    Failure of the peroxisome proliferator WY-14,643 to initiate growth-selectable foci in rat liver

    Toxicology

    (1989)
  • A.J. Cohen et al.

    Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man

    Food and Cosmetics Toxicology

    (1981)
  • A.S. Dabholkar

    Vitamin E deficiency as hepatic peroxisomal proliferator: electron microscopic evidence

    Cell Biology International Reports

    (1981)
  • A.B. De Angelo et al.

    Inhibition of development of preneoplastic lesions in the livers of rats fed a weakly carcinogenic environmental contaminant

    Cancer Letters

    (1983)
  • F.A. De La Iglesia et al.

    Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term Gemfibrozil treatment

    Atherosclerosis

    (1982)
  • C. Dreyer et al.

    Control of the peroxisomal beta oxidation pathway by a novel family of nuclear hormone receptors

    Cell

    (1992)
  • P.I. Eacho et al.

    Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species

    Toxicology and Applied Pharmacology

    (1986)
  • P.I. Eacho et al.

    Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: structure-activity relationships

    Toxicology and Applied Pharmacology

    (1989)
  • C.R. Elcombe et al.

    Biochemical, histological and ultrastructural changes in rat and mouse liver following the administration of trichlorethylene; possible relevance to species differences in hepatocarcinogenicity

    Toxicology and Applied Pharmacology

    (1985)
  • J.E. Fitzgerald et al.

    Preclinical toxicology studies with the lipid-regulating agent gemcadiol

    Fundamental and Applied Toxicology

    (1986)
  • F.L. Fort et al.

    Cetaben versus clofibrate comparison of toxicity and peroxisome proliferation in rats

    Toxicology

    (1983)
  • P.S. Foxworthy et al.

    Effect of ciprofibrate, benzafibrate and LY171883 on peroxisomal β-oxidation in cultured rat, dog, and rhesus monkey hepatocytes

    Toxicology and Applied Pharmacology

    (1990)
  • A.E. Ganning et al.

    Effects of dietary di(2-ethylhexyl) phthalate on the structure and function of rat hepatocytes

    Biochemica et Biophysica Acta

    (1983)
  • P. Gariot et al.

    Morphometric study of human hepatic cell modifications induced by fenofibrate

    Metabolism

    (1987)
  • H.P. Glauert et al.

    Lack of initiating activity of the peroxisome proliferator ciprofibrate in two-stage hepatocarcinogenesis

    Cancer Letters

    (1989)
  • S.K. Goel et al.

    Lack of covalent binding of peroxisome proliferators nafenopin and Wy-14 643 to DNA in vivo and in vitro

    Toxicology Letters

    (1985)
  • T.L. Goldsworthy et al.

    Chlorinated hydrocarbon-induced peroxisomal enzyme activity in relation to species and organ carcinogenicit

    Toxicology and Applied Pharmacology

    (1987)
  • T.J.B. Gray et al.

    Peroxisome proliferation in cultured rat hepatocytes produced by clofibrate and phthalic ester metabolites

    Toxicology Letters

    (1982)
  • M. Hanefeld et al.

    Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man

    Atherosclerosis

    (1983)
  • J.P. Hardwick et al.

    Isolation, complementary DNA sequence and regulation of rat hepatic lauric acid Ω-oxidation (cytochrome P-450)

    Journal of Biological Chemistry

    (1987)
  • E.H. Harrison

    Action of clofibrate and its analogs in rats

  • K.L. Allen et al.

    Comparative studies on peroxisomal enzyme induction in hepatocytes from rat, cynomolgus monkey and human by hypolipidaemic drugs

    Toxicologist

    (1987)
  • J. Ashby et al.

    Cell replication and unscheduled DNA synthesis (UDS) activity of low molecular weight chlorinated paraffins in the rat liver in vivo

    Mutagenesis

    (1990)
  • D.L. Azarnoff et al.

    Structure activity relationships of clofibrate-like compounds on lipid metabolism

  • E.D. Barber et al.

    Peroxisome induction studies on seven phthalate esters

    Toxicology and Industrial Health

    (1987)
  • S. Barni et al.

    Effects of isoprenaline treatment on the rat liver parenchyma

    Acta analytica

    (1981)
  • M. Bassi

    Electron microscopy of rat liver after carbon tetrachloride poisoning

    Experimental Cell Research

    (1960)
  • D.R. Bell et al.

    Localisation and differential induction of cytochrome P450IVA and acyl CoA oxidase in rat liver

    Biochemical Journal

    (1991)
  • D.R. Bell et al.

    Induction of acyl CoA oxidase and P450IVA1 in rat primary hepatocyte cultures by peroxisome proliferators

    Biochemical Journal

    (1991)
  • P. Bentley et al.

    Investigations on the mechanism of liver tumour induction by peroxisome proliferators

    Archives of Toxicology

    (1987)
  • P. Bentley et al.

    Mechanisms of tumour induction by peroxisome proliferators

    Archives of Toxicology

    (1988)
  • Cited by (269)

    • Carcinogenicity

      2018, Comprehensive Toxicology: Third Edition
    • Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis

      2014, Biochimie
      Citation Excerpt :

      As shown in Fig. 2, under these conditions, human hepatocytes did show an observable increase in the number of peroxisomes when treated with ciprofibrate [34]. Some other studies showed that peroxisome proliferators have little effect, if any, on human liver cells [68–70]. Although preliminary in nature these observations suggest that additional rigorous studies are needed to extend this work.

    View all citing articles on Scopus

    Present address: Ciba-Geigy, CH-4002, Basel, Switzerland

    §

    Present address: Zeneca CTL, Alderley Park, Macclesfield, Cheshire SK104TJ, UK

    Present address: Robens Institute of Health and Safety, University of Surrey, Guildford GU2 5XH

    Present address: ECETOC, Av. E. Van Nieuwenhuyse 4 (Bte 6), B-1160 Brussels, Belgium

    ∗∗

    Present address: Hüls AG, 45764, Germany.

    View full text